Document:

Amended Patent Assignment and License Agreement

 ORCHID BIOSCIENCES, INC. HAS REQUESTED THAT THE MARKED PORTIONS OF THIS DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
 [*] CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS. 
  
 Exhibit 10.25 
  
 Agreement to Amend Patent Assignment and License Agreement 
  
 DATED JULY 7, 2003 (“AMENDMENT DATE”) 
  

			
		
	 BETWEEN:
	  	Diatech Pty Ltd (ACD 069052 197) a corporation whose legal address is c/o School of Life Sciences, Queensland University of Technology, 2 George Street, Brisbane, Queensland 4000
(“DIATECH”), GeneCo Pty Ltd (CAN 010 737 603) a corporation, whose legal address is 4th Floor, O
Block Podium, Queensland University of Technology, 2 George Street, Brisbane, Queensland 4000, Australia (“GENECO”) and Queensland University of Technology, a body corporate constituted pursuant to the provisions of the Queensland
University of Technology Act 1998 (Qld) whose legal address is 2 George Street, Brisbane, Queensland 4000 Australia (“QUT”)
		
	 	  	(together the “ASSIGNORS”)
		
	 AND
	  	ORCHID BIOSCIENCES, INC., a Delaware corporation having a principal place of business at 4390 U.S. Route One, Princeton, NJ 08540
		
	 	  	(“ORCHID”)

  
 AGREE AS FOLLOWS: 

 
 1. BACKGROUND 
  
 1.1 ASSIGNORS assigned to AFFYMETRIX, INC. (“ AFFYMETRIX”) certain rights relating to a Patent entitled
“Detection of a Nucleic Acid Sequence or a Change Therein” pursuant to a Patent Assignment and License Agreement dated February 28, 2000 and effective as of March 20, 2000 (“Original Agreement”). Those rights are defined as
“ASSIGNED PATENT RIGHTS” in the Original Agreement. 
  
 1.2 With the consent of ASSIGNORS, ORCHID thereafter acquired from AFFYMETRIX the ASSIGNED PATENT RIGHTS and assumed all of AFFYMETRIX’s rights and obligations under the Original Agreement, under an Assignment Agreement dated as of
July 18, 2001 (“Assignment Agreement”). subject to the terms and conditions of the Original Agreement. 
  
 1.3 ORCHID and ASSIGNORS have agreed to amend certain payment and other obligations under the Original Agreement and to otherwise amend and restate the
Original Agreement in its entirety and to reaffirm their continuing obligations thereunder as set forth herein. 
  
 2. AMENDMENT 
  
 2.1 ASSIGNORS and Orchid agree effective as of the AMENDMENT DATE, the provisions of the Original Agreement are varied as set out in Schedule 1 to this
Agreement. Subject to the amendments specified in Schedule 1 to this Agreement, the parties reaffirm the provisions of the Original Agreement as between them following the execution by ORCHID and AFFYMETRIX of the Assignment Agreement. 

 3. APPLICABLE LAW 
  
 3.1 This Agreement will be construed, interpreted, and applied in accordance with the laws of the State of California in the United States. 
  
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement in
duplicate originals by their duly authorized officers or representatives. 
  

	By:	

  

							
	 DIATECH
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 Name:
	 	  

	 	 Name:
	 	  

	 Title:
	 	  

	 	 Title:
	 	  

	 Date:
	 	  

	 	 Date:
	 	  

			
	 GENECO
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 Name:
	 	  

	 	 Name:
	 	  

	 Title:
	 	  

	 	 Title:
	 	  

	 Date:
	 	  

	 	 Date:
	 	  

							
	 QUT
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	

	 Name:
	 	  

	 	 Name:
	 	

	 Title:
	 	  

	 	 Title:
	 	

	 Date:
	 	  

	 	 Date:
	 	

			
	 ORCHID BIOSCIENCES, INC.
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 Name:
	 	  

	 	 Name:
	 	  

	 Title:
	 	  

	 	 Title:
	 	  

	 Date:
	 	  

	 	 Date:
	 	  

 SCHEDULE 1 
 AMENDMENTS TO ORIGINAL AGREEMENT 
  
 Patent Assignment and License Agreement 
  
 Dated:
February 28, 2000 
  

			
		
	BETWEEN:	  	Diatech Pty Ltd (ACD 069052 197) a corporation whose legal address is c/o School of Life Sciences, Queensland University of Technology, 2 George Street, Brisbane, Queensland 4000
(“DIATECH”), GeneCo Pty Ltd (CAN 010 737 603) a corporation, whose legal address is 4th Floor, O
Block Podium, Queensland University of Technology, 2 George Street, Brisbane, Queensland 4000, Australia (“GENECO”) and Queensland University of Technology, a body corporate constituted pursuant to the provisions of the Queensland
University of Technology Act 1998 (Qld) whose legal address is 2 George Street, Brisbane, Queensland 4000 Australia (“QUT”)
		
	 	  	 (together the “ASSIGNORS”)

		
	AND:	  	ORCHID BIOSCIENCES, INC., a Delaware corporation having a principal place of business at 4390 U.S. Route One, Princeton, NJ 08540
		
	 	  	ORCHID

  
 AGREE AS FOLLOWS: 

 
 1. BACKGROUND 
  
 1.1 GENECO is the current owner of a Patent entitled “Detection of a Nucleic Acid Sequence or a Change Therein”
and ASSIGNED PATENT RIGHTS as defined below. 
  
 1.2 GENECO
granted to QUT a world-wide exclusive license of certain of the ASSIGNED PATENT RIGHTS (attached as Exhibit A), and QUT granted to DIATECH a world-wide exclusive sublicense of those same rights (attached as Exhibit B). 
  
 1.3 ASSIGNORS assigned the ASSIGNED PATIENT RIGHTS to AFFYMETRIX, who wished
to acquire the ASSIGNED PATENT RIGHTS for the purpose of undertaking development and to manufacture, use, and distribute certain reagents. 
  
 1.4 AFFYMETRIX, with the consent of GENECO, QUT and DIATECH, assigned the ASSIGNED PATENT RIGHTS TO ORCHID. 
  
 2. DEFINITIONS 
  
 2.1 “AFFYMETRIX” means AFFYMETRIX Inc., a Delaware corporation having a principal place of business at 3380
Central Expressway, Santa Clara, CA 95051. 

 2.2 “ASSIGNED PATENT RIGHTS” means the patents, patent applications and license agreements
(including all rights of any party contained therein) set forth on Exhibit C and assigned to ORCHID pursuant to Section 3 and the Patent Assignment attached as Exhibit D, which GENECO executed on the EFFECTIVE DATE, including without limitation, the
underlying inventions to the patents and patent applications, and any and all Letters Patents whether U.S. or foreign that are or may be granted therefrom including without limitation any extensions, continuations, continuations-in-part, divisions,
reissues, improvements and renewals thereof, or other equivalents thereof, and trade secrets and know-how related thereto which are in the possession of ASSIGNORS as of the EFFECTIVE DATE, and further, all rights and privileges pertaining to the
ASSIGNED PATENT RIGHTS including without limitation the right, if any, to claim the right to priority thereto and to sue or bring other actions for past, present and future infringement thereof. 
  
 2.3 “AFFILIATE” means any corporation or other business entity in
which ORCHID owns or controls, directly or indirectly, at least ten percent (10%) of the outstanding stock or other voting rights entitled to elect directors or in which ORCHID is owned or controlled directly or indirectly by at least ten percent
(10%) of the outstanding stock or other voting rights entitled to elect directors; but in any country where the local law does not permit foreign equity participation of at least ten percent (10%), then an “AFFILIATE” includes any company
in which ORCHID owns or controls, or is owned or controlled by, directly or indirectly, the maximum percentage of outstanding stock or voting rights permitted by local law. 
  
 2.4 “EFFECTIVE DATE” means March 20, 2000 being the date on which GENECO notified AFFYMETRIX in writing that the
R&D syndication established by the TRANSACTION DOCUMENTS had wound-up and that GENECO had fulfilled all of its obligations under and to all parties to the TRANSACTIONS DOCUMENTS. 
  
 2.5 “TERRITORY” means Australia. 
  
 2.6 “MEMBER(S)” shall mean members of the CRC that have signed an agreement with CRC for such membership.

  
 2.7 “TRANSACTION DOCUMENTS” means the following
agreements, complete copies of which were provided to ORCHID for due diligence purposes prior to the execution of this Agreement, which established the R&D syndication knows as the Cystic Fibrosis Joint Venture: 
  
 (a) License Agreements dated 30 June 1994 between: 
  
 (i) GENECO and Australasian Drug Development Limited (“ADDL”) and

  
 (ii) Auspep Pty Ltd and ADDL. 

 (b) Procedures Memorandum dated 30 June 1994 between all parties to the Cystic Fibrosis Joint Venture.

  
 (c) License, Research and Commercialisation Agreement dated 30
June 1994 between ADDL, GENECO, Auspep Pty Ltd, and each of Radtel 1 Pty Ltd, Radmed 2 Pty Ltd and Radtel 3 Pty Ltd (together “Investor”). 
  
 (d) Deposit Agreement dated 30 June 1994 between Bankers Trust Australia Limited (“Lender”), ADDL and GENECO. 
  
 (e) Company Put Option Agreements dated 30 June 1994 between: 
  
 (i) GENECO, ADDL, Edingbay Pty Ltd, the Lender and BT Financial Management
Pty Ltd (“Manager”); 
  
 (ii) GENECO, ADDL, Twentieth
Apelda Pty Ltd, the Lender and the Manager; and 
  
 (iii) GENECO,
ADDL, Edzell Holdings Pty Ltd, the Lender and the Manager. 
  
 3. ASSIGNMENT

  
 3.1 Assignment. On the EFFECTIVE DATE the
ASSIGNORS hereby jointly and severally assign, transfer and convey to ORCHID all of ASSIGNORS’ right, title, and interest throughout the world in and to said ASSIGNED PATENT RIGHTS. 
  
 3.2 Further Assignment. On the EFFECTIVE DATE the ASSIGNORS jointly and severally further assign to and empower
ORCHID, its successors, assigns or nominees, all rights to make applications for patents or other forms of protection for ASSIGNED PATENT RIGHTS, as well as to claim and receive the benefit of the right of priority provided by the International
Convention for the Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it, and the right to invoke and claim such right of priority without further written or oral authorization. 
  
 3.3 Authorization of Patent and Trademark Office to Record. ASSIGNORS
jointly and severally further agree that the agreement attached as Exhibit D, which GENECO must execute on the EFFECTIVE DATE, shall be deemed a full legal and formal equivalent of any assignment, consent to file or like document which may be
required in any country for any purpose regarding the subject matter hereof, as well as constituting proof of the right of ORCHID or its successors, assigns or nominees to apply for patent or other proper protection for said inventions, and to claim
the aforesaid benefits of the right of priority provided by the International Convention for the Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it. 

 3.4 Further Assurances. ASSIGNORS jointly and severally agree to take such further actions and to
execute such documents as ORCHID may reasonably request to effect or confirm the conveyance to ORCHID of the ASSIGNED PATENT RIGHTS and any improvements thereunder. 
  
 4. GRANT OF LICENSES TO THE TECHNOLOGY 
  
 4.1 Research License. Subject to the terms and conditions of this Agreement, ORCHID hereby grants to the ASSIGNORS a non-exclusive,
non-transferable (except as permitted by this Agreement), fully-paid right to use the ASSIGNED PATENT RIGHTS solely for the purpose of conducting internal non-commercial, non-profit research purposes, solely in the TERRITORY. Such license shall be
sublicensable only by DIATECH and only to MEMBERS as approved by ORCHID pursuant to Section 4.3. 
  
 4.2 Genotyping Service License. Subject to the terms and conditions of this Agreement, ORCHID hereby grants to DIATECH, with the right to
sublicense only to CRC members as approved by ORCHID pursuant to Section 4.3, a non-transferable (except as permitted by this Agreement), non-exclusive, fully-paid right to use the ASSIGNED PATENT RIGHTS to offer genotyping services (but only
genotyping services that do not use micro-arrays) only I the TERRITORY and provided that DIATECH and the MEMBERS only offer and perform such services on genetic materials originating or derived solely in the TERRITORY. 
  
 4.3 Member Approved Rights. A list of MEMBERS approved by ORCHID to
receive a sublicense from DIATECH under Sections 4.1 and 4.2 above is attached as Exhibit E. DIATICH may make additions to this list by written consent which shall not be unreasonably withheld (for the avoidance of doubt, the withholding of consent
regarding a competitor of ORCHID shall not be considered unreasonable). Such request shall designate the name of the member, any affiliates of the member who will have LICENSED RIGHTS (defined as any rights licensed to a member under Sections 4.1 or
4.2 of this agreement) under this agreement through their affiliation with the member if such member is approved by ORCHID, the address of such parties, a brief description of the Business of the member, and a general description of the research to
be performed. ORCHID shall have 30 days from a request to add to Exhibit E to respond to such request with its consent or denial of such request. If ORCHID fails to respond within 30 days, the member shall be deemed to have been approved and shall
be added to the list. Upon the grant of a sublicense under Sections 4.1 and 4.2 to a member, such member shall sign a license agreement with DIATECH that is at least as protective of ORCHID as this agreement. Such license agreement shall also
provide that in the event of a material breach of the license agreement that is not corrected within thirty (30) days of written notice to the member by ORCHID. ORCHID or DIATECH shall have the right to immediately terminate the sublicense. Each
sublicense granted by DIATECH to a MEMBER pursuant to this Section 4 above shall continue for the term of this Agreement unless ORCHID provides notice to DIATECH of its withdrawal of consent for any sublicense to any specific MEMBER prior to
November 1 of any year due to the failure of that specific MEMBER to rectify a material breach. ORCHID shall be provided a copy of each sublicense granted by DIATECH under this Agreement. 

 4.4 Right of First Refusal. The ASSIGNORS, and their sublicensees, grant to ORCHID the first right
to license any patents, patent applications or other related rights arising from their use of the ASSIGNED PATENT RIGHTS pursuant to Section 4.1, 4.2 and 4.3. ORCHID shall be notified of such rights prior to their being offered to any third party.

  
 5. PAYMENTS 
  
 5.1 On the AMENDMENT DATE, ORCHID shall pay to QUT and DIATECH a
non-refundable payment of US$375,000.00 as follows: 
  
 (a) US$187,500.00 to QUT; and 
  
 (b)
US$187,500 to DIATECH. 
  
 5.2 In addition to the payments
referred to in Section 5.1, ORCHID shall pay to ASSIGNORS an aggregate non-refundable sum of US$600,000 in four equal annual installments of US$150,000 each within fourteen (14) days of each of the four anniversary dates following the AMENDMENT
DATE. ORCHID shall pay each installment to QUT and DIATECH in equal shares (50% each). 
  
 5.3 ORCHID will make the payments referred to in Sections 5.1 and 5.2 by cheques, or by other means if mutually agreed by the parties, to the ASSIGNORS forwarded to each party at the address shown in Section 14
(Notices). 
  
 5.4 From the EFFECTIVE DATE until 5 years after the
expiration of this Agreement, the parties shall keep true and complete records, including all certifications, advice or any correspondence, related to any taxation (or lack thereof) by any government or governmental agency resulting from any
payments made by one party to another under this Agreement. 
  
 5.5 ORCHID must provide the ASSIGNORS upon request written verification of the amount of any tax paid by it in the US relating to any payments made by ORCHID to the ASSIGNORS under this Agreement, to enable the ASSIGNORS to clam if
appropriate, a corresponding tax credit in Australia. 
  
 6. LIFE OF THE
AGREEMENT 
  
 6.1 Unless otherwise terminated by the
operation of law or by acts of the parties in accordance with the terms of this Agreement, this Agreement will be in force from the EFFECTIVE DATE and will remain in effect for the life of the last-to-expire patent licensed under this Agreement.

 6.2 ASSIGNORS may terminate this Agreement immediately on written notice to ORCHID if ORCHID fails to pay
any sum due to any of the ASSIGNORS under this Agreement and the amount remains outstanding for a period of 90 days after the receipt of notice from ASSIGNORS of such failure to pay. 
  
 6.3 ORCHID may terminate any licenses granted under this Agreement as to any of the ASSIGNORS if any such party materially
breaches a license granted by this agreement and fails to cure such breach within 90 days of notice of such breach by the other party. 
  
 6.4 If the ASSIGNORS terminate this Agreement pursuant to Section 6.2, and as at the date of such termination the total payments that have been made by
ORCHID to ASSIGNORS pursuant under Section 5.1 and 5.2 are less than US$675,000, then ORCHID must re-assign to each of the ASSIGNORS their ASSIGNED PATENT RIGHTS in their entirely and at no cost to the ASSIGNORS except as agreed by the ASSIGNORS.

  
 6.5 Any termination of this Agreement shall not affect the
rights and obligations set forth in the following articles: Section 6.4, Sections 9 – 12, Section 14, Sections 16 – 17, and Section 20. 
  
 6.6 Any termination of this Agreement will not relieve ORCHID of its obligation to pay any moneys due to owing at the time of such termination and will
not relieve any obligations, of either party to the other party, established prior to termination. 
  
 7. USE OF NAMES AND TRADEMARKS 
  
 7.1 Nothing contained in this Agreement will be construed as conferring any right to use in advertising, publicity or other promotional activities, any name, trademark, trade name, or other designation of either party hereto by the other
(including any contraction, abbreviation, or simulation of any of the foregoing). 
  
 8. REPRESENTATION AND WARRANTIES 
  
 8.1 Each of
the ASSIGNORS jointly and severally warrants to ORCHID that as at the EFFECTIVE DATE is has the lawful right to assign the relevant ASSIGNED PATENT RIGHTS to ORCHID and that nothing in, or related to, the TRANSACTION DOCUMENTS prevents ASSIGNORS
from assigning all rights to the ASSIGNED PATENTS as contemplated by this Agreement. 
  
 8.2 Each of the ASSIGNORS severally warrants that as at the EFFECTIVE DATE: 
  
 (a) no licenses currently exist to the ASSIGNED PATENT RIGHTS; and 
  
 (b) any prior licenses to such rights have been terminated or assigned to ORCHID. 

 8.3 Nothing in this Agreement is or will be construed as: 
  
 (a) A warranty or representation by ASSIGNORS as to the validity,
enforceability or scope of any ASSIGNED PATENT RIGHTS; or 
  
 (b)
A warranty or representation that anything made, used, sold, or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of patents of third parties; or 
  
 (c) Conferring by implication, estoppel, or otherwise any rights under any
patents of ASSIGNORS other than ASSIGNED PATENT RIGHTS as defined herein, regardless of whether such patents are dominant or subordinate to ASSIGNED PATENT RIGHTS; or 
  
 (d) An obligation to furnish any know how, not provided in ASSIGNED PATENT RIGHTS. 
  
 9. LIABILITY LIMITATION 
  
 9.1 IN NO EVENT WILL ANY PARTY TO THIS AGREEMENT BE LIABLE FOR ANY INCIDENTALY, SPECIAL OR CONSEQUENTIAL DAMAGES, INCLUDING
BUT NOT LIMITED TO LOSS OF REVENUE, PROFITS, GOODWILL OR REPUTATION, BARGAIN OR OPPORTUNITIES, RESULTING FROM EXERCISE OF THE ASSIGNMENT OF THE ASSIGNED PATENT RIGHTS OR FROM ORCHID’S SALE OR TRANSFER OF ANY PRODUCT OR SERVICE THAT RESULTS OR
IS DEVELOPED FROM, OR INCORPORATES ANY COMPONENT OF THE ASSIGNED PATENT RIGHTS OR THE USE BY ANY THIRD PARTY OF PRODUCTS OR SERVICES. 
  
 10. PATENT INFRINGEMENT 
  
 10.1 ORCHID is responsible for and will pay all patent prosecution expenses including all filing and associated fees after the EFFECTIVE DATE of this
Agreement, and all such expenses incurred before the EFFECTIVE DATE of the Agreement for applications filed in AT, BE, CH, DK, ES, LU, NL and SE. ORCHID will control the prosecution of all applications and post-issuance matters after the EFFECTIVE
DATE of this Agreement. 
  
 10.2 ASSIGNORS will cooperate,
including being joined as a party if reasonably necessary (with all related costs to be paid by ORCHID), with ORCHID in litigation instituted with regard to the ASSIGNED PATENT RIGHTS but at the expense of ORCHID. Such litigation will be controlled
by ORCHID. The ASSIGNORS will use their respective best efforts to obtain the cooperation, in such action of any inventors or other persons associated with the ASSIGNED PATENT RIGHTS. 

 11. INDEMNIFICATION 
  
 11.1 ORCHID will, and will cause its affiliates, to indemnify, hold harmless, and defend ASSIGNORS, its officers, employees, and agents; sponsor(s) of the
research that led to the ASSIGNED PATENT RIGHTS; and the inventors of any patents and patent applications in ASSIGNORS’ PATENT RIGHTS and their employers against any and all claims, suits, losses, damages, costs, fees, and expenses resulting
from or arising out of exercise of the ASSIGNED PATENT RIGHTS or any license, including, but not be limited to, any product liability, provided that (i) ORCHID is promptly notified in writing of such claim or suit, (ii) ORCHID has the sole control
of and must conduct the defense and/or settlement thereof, and (iii) ASSIGNORS furnish to ORCHID, on request, information available to ASSIGNORS for such defense. However, ORCHID is in no way authorized to agree to any settlement, compromise or the
like which would compromise the ASSIGNED PATENT RIGHTS and/or would require that ASSIGNORS make any payment, or bear other obligations beyond those required by this Agreement. 
  
 12. ARBITRATION AND DISPUTES 
  
 12.1 Except that either party may seek urgent injunctive or similar relief from a court, any dispute, controversy or claim arising out of or in relation
to this Agreement or at law, or the breach, termination or invalidity thereof, that cannot be settled amicably by agreement of the parties hereto, may be finally settled by arbitration in accordance with the World Intellectual Property Organisation
Arbitration Rules by one or more arbitrators appointed in accordance with said rules; provided, however, that arbitration proceedings may not be instituted until the party alleging breach of this Agreement by the other party has given the other
party not less than 90 days to remedy any alleged breach and the other party has failed to do so. The place of arbitration shall be the State of California in the United States. The parties shall share the cost of the arbitrator equally but each
party will bear their own costs of such arbitration including their own attorney’s fees. 
  
 13. ASSIGNMENT 
  
 13.1
This Agreement is binding upon and shall inure to the benefit of the parties, their successors and assigns. This Agreement may be assigned by each party with written consent of all other parties, which shall not be unreasonably withheld provided at
least thirty (30) days notice has been given by the party wishing to assign, except that no such consent from ASSIGNORS shall be necessary for an assignment by ORCHID in the event of a sale or transfer of all or substantially all of its assets
whether by sale, merger or otherwise. 

 14. NOTICES 
  
 14.1 All notices under this Agreement will be deemed to have been fully given when done in writing and deposited in the United States mail or Australian
mail as the case may be, registered or certified, and addressed as follows: 
  

			
	 To ASSIGNORS:
	  	 
	 	  	GENECO
	 	  	C/o Office of Commercial Services
	 	  	Queensland University of Technology
	 	  	GPO Box 2434
	 	  	BRISBANE QLD 4001
	 	  	Australia
	 	  	Fax: +617 3864 1512
	 	  	Attn.: The Company Secretary
		
	 	  	AND
		
	 	  	Diatech
	 	  	C/o School of Life Sciences
	 	  	Queensland University of Technology
	 	  	2 George Street
	 	  	BRISBANE QLD 4000
	 	  	Australia
	 	  	Fax: +617 3864 1534
	 	  	Attn: The Company Secretary
		
	 	  	AND
		
	 	  	QUT
	 	  	C/o Office of Commercial Services
	 	  	Queensland University of Technology
	 	  	GPO Box 2434
	 	  	BRISBANE QLD 4001
	 	  	Australia
	 	  	Fax: +617 3864 1512
	 	  	Attn.: Manager, Office of Commercial Services

  
 Any party may change
its address upon written notice to the other parties. 
  
 15. WAIVER

  
 15.1 The failure of either party to assert a right
hereunder or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. 
  
 15.2 None of the terms, covenants, and conditions of this Agreement can be
waived except by the written consent of the party waiving compliance. 

 16. CONFIDENTIALITY 
  
 16.1 ORCHID and ASSIGNORS respectively will hold each party’s proprietary business, terms of this Agreement, patent prosecution material, trade
secrets and know-how, and technical information and other proprietary information in confidence and against disclosure to third parties with at least the same degree of care as it exercises to protect its own data and license agreements of a similar
nature. 
  
 16.2 Nothing contained herein will in any way restrict
or impair the right of ORCHID or ASSIGNORS to use, disclose, or otherwise deal with any information or data which: 
  
 (a) at the time of disclosure to a receiving party is generally available to the public or thereafter becomes generally available to the public by
publication or otherwise through no act of the receiving party: 
  
 (b) the receiving party can show by written record was in its possession prior to the time of disclosure to it hereunder and was not acquired directly or indirectly from the disclosing party; 
  
 (c) is independently made available to the receiving party without
restrictions as a matter of right by a third party; 
  
 (d) is
subject to disclosure under the California Public Records Act, any applicable stock exchange or other requirements of law; 
  
 (e) is provided in confidence to a party’s professional advisers for the purposes of seeking professional advice; or 
  
 (f) is required to be disclosed to prosecute or defend any claim, action,
proceeding or demand. 
  
 16.3 It is understood that ASSIGNORS
will be free to release to the inventors and senior administrators employed by ASSIGNORS the terms and conditions of this Agreement upon their request. If such release is made, ASSIGNORS will inform such employees of the confidentiality obligations
set forth above and will request that they do not disclose such terms and conditions to others. 
  
 16.4 ORCHID and ASSIGNORS agree to destroy or return to the disclosing party proprietary information received from the other in its possession within
fifteen (15) days following the effective date of termination of this Agreement. However, each party may retain one copy of proprietary information of the other solely for archival purposes in non-working files for the sole purpose of verifying the
ownership of the proprietary information, provided such proprietary information, provided such proprietary information will be subject to the confidentiality provision set forth in Section 16.1. ORCHID and ASSIGNORS agree to provide each other,
within thirty (30) days following termination of this Agreement, with a written notice that proprietary information has been returned or destroyed. 

 16.5 The terms of this Section 16 (Confidentiality) will expire in five (5) years from the official date
of termination of this Agreement. 
  
 17. ATTORNEY’S FEES 

 
 17.1 In the event of legal action, other than arbitration conducted in
accordance with Section 12, taken by a party against the other arising out of this Agreement, the prevailing party will be entitled to reasonable attorney’s fees in addition to costs and necessary disbursements. 
  
 18. FORCE MAJEURE 
  
 18.1 The parties to this Agreement shall be excused from any performance required hereunder if such performance is rendered
impossible or unfeasible due to any catastrophes or other major events beyond their reasonable control, including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other
serious labor disputes; and floods, fires, explosions, or other natural disasters. When such events have abated, the parties’ respective obligations hereunder will resume. 
  
 19. SEVERABILITY 
  
 19.1 The provisions of this Agreement are severable, and in the event that any provision of this Agreement will be determined to be invalid or
unenforceable under any controlling body of law, such invalidity or enforceability will not in any way affect the validity or enforceability of the remaining provisions hereof. 
  
 20. APPLICABLE LAW 
  
 20.1 THIS AGREEMENT WILL BE CONSTRUED, INTERPRETED, AND APPLIED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, U.S.A. QUESTIONS CONCERNING THE
LAW AND EFFECT OF THE ASSIGNORS’ PATENT RIGHTS WILL BE DETERMINED BY THE LAW OF THE COUNTRY IN WHICH THE RELEVANT PATENT WAS GRANTED. 
  
 21. SCOPE OF AGREEMENT 
  
 21.1 This Agreement incorporates the entire agreement between the parties with respect to the subject matter hereof, and this Agreement may be altered or
modified only by written amendment duly executed by the parties hereto. 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate originals by their duly
authorized officers or representatives. 
  

	By:	

  

							
	 DIATECH
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 Name:
	 	  

	 	 Name:
	 	  

	 Title:
	 	  

	 	 Title:
	 	  

	 Date:
	 	  

	 	 Date:
	 	  

			
	 GENECO
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 Name:
	 	  

	 	 Name:
	 	  

	 Title:
	 	  

	 	 Title:
	 	  

	 Date:
	 	  

	 	 Date:
	 	  

			
	 QUT
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 Name:
	 	  

	 	 Name:
	 	  

	 Title:
	 	  

	 	 Title:
	 	  

	 Date:
	 	  

	 	 Date:
	 	  

			
	 ORCHID BIOSCIENCES, INC.
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 Name:
	 	  

	 	 Name:
	 	  

	 Title:
	 	  

	 	 Title:
	 	  

	 Date:
	 	  

	 	 Date:
	 	  

 Exhibit A 
  

QUT License 
  

 E-1 

 Exhibit B 
  

Diatech License 
  

 E-2 

 Exhibit C 
  

Assigned Patents Rights 
  
  
 [*] 
  

							
	 Country

	 	 Patent Application No.

	 	 Patent Number

	 	 Issue Date

	[*]
	 USA
	 	08/429659	 	5856092	 	5 January 1999
	[*]

  

 Exhibit D 
  

Patent Assignment Document 
 ASSIGNMENT 

 
 WHEREAS, GeneCo Pty Ltd, 4th Floor, O Block Podium, Queensland University of Technology, 2 George Street, Brisbane, Queensland 4000, Australia, hereinafter referred to as
“Assignor”, is the owner of rights in certain new and useful improvements as described and set forth in the applications for United States Letters Patent and corresponding filings worldwide listed in Attachment 1. 
  
 WHEREAS, Affymetrix, Inc., a corporation of the state of Delaware, located at 3380 Central
Expressway, Santa Clara, CA 95051, hereinafter referred to as “ASSIGNEE”, is desirous of acquiring an interest in the invention and applications and in any Letters Patents and Registrations that my be granted on the same; 
  
 For good and valuable consideration, receipt of which is hereby acknowledged by Assignor,
Assignor has assigned, and by these presents does assign to Assignee all Assignor’s right, title and interest in and to the invention, including all patent filings listed in Attachment 1, all counterparts deriving priority therefrom (including
patent, utility model and industrial designs), and in and to an Letters Patent and Registrations which may hereafter be granted on the same in the United States and all countries throughout the world, and to claim the priority from the applications
as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee’s successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this assignment not
been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof. 
  
 Assignor further agrees that Assignor will, without charge to Assignee, but at
Assignee’s expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including
patent applications and instruments of transfer and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title
thereto in Assignee, or Assignee’s successors and assigns. 
  
 IN TESTIMONY
WHEREOF, this Assignment is executed 
  

			
	 Signed:
	 	  

	 Name:
	 	  

	 Position: Director

	 Assignor: GeneCo Pty Ltd.

  

 E-4 

			
	 Signed:
	 	  

	 Name:
	 	  

	 Position: Director/Secretary

	
	 Assignor: GeneCo Pty Ltd.

  

			
	THE COMMON SEAL of GENECO	 	)
	PTY LTD was affixed to this Agreement	 	)
	in accordance with its Constitution in	 	)
	The presence of:	 	)

  

			
	 Signed:
	 	  

	 Name:
	 	  

	 Position: Director/Secretary

	
	 Assignee: Affymetrix, Inc.

  

			
	STATE OF CALIFORNIA	 	)
	 	 	)         ss.
	COUNTY OF	 	)

  
 On                    , before me,
                    , personally appeared            personally known to me
(or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument, and acknowledged to me that he/she executed the same in his/her authorized capacity, and that by his/her signature on the
instrument th person, or the entity upon behalf of which the person acted, executed the instrument. 
  
 WITNESS my hand and official seal. 
  

	
	  

	 NOTARY PUBLIC

  
 My Commission
Expires:                         
  

 E-5 

 Attachment 1 to Patent Assignment Document 
  
 Assigned Patents Rights 
  
  
 [*] 
  

							
	 Country

	 	 Patent Application No.

	 	 Patent Number

	 	 Issue Date

	[*]
	 USA
	 	08/429659	 	5856092	 	5 January 1999
	[*]

  

 Exhibit E 
  

List of Approved CRC Members 
  
  
 [*] 
  

 E-7Settlement Agreement

 ORCHID BIOSCIENCES, INC. HAS REQUESTED THAT THE MARKED PORTIONS OF THIS DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
 [*] CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS. 
  
 Exhibit 10.27 
  
 SETTLEMENT AGREEMENT 
  
 This Settlement Agreement (“Agreement”) is entered into as of 6th day of
August, 2002, by and between SAINT LOUIS UNIVERSITY, a non-profit organization organized and existing under the laws of the State of Missouri (“SLU”), and ORCHID BIOSCIENCES, INC., a Delaware Corporation (“ORCHID”). 

 
 WHEREAS, ORCHID commenced a declaratory judgment action in the
United States District Court for the Southern District of California that was transferred to the United States District Court for the Eastern District of Missouri (Civil Action No. 4:02CV00179JCH, U.S.D.C., E.D. of MO) against SLU (the
“Action”) in connection with the parties’ rights and obligations with respect to U.S. Patent No. 5,846,710 (the “‘710 Patent”); and 
  
 WHEREAS, SLU filed a counterclaim against ORCHID alleging patent infringement of the ‘710 Patent. 
  
 WHEREAS, the parties each have denied any liability for the
allegations contained in the Action and wish to resolve their disputes on the terms and subject to the conditions therein; 
  
 NOW, THEREFORE, in consideration of the mutual promises, covenants and agreements contained herein, and other good and valuable consideration, the
sufficiency of which are hereby acknowledged, and in full satisfaction of all claims alleged by the parties in the Action, it is hereby agreed as follows: 
  

	 	1.	Assignment. 

  

	 	1.1	Subject to the terms and conditions herein set forth, SLU hereby assigns, transfers and sets over to ORCHID the entire right, title and interest of SLU in and to the ‘710
Patent, including: (i) any license agreements with respect to the ‘710 Patent as listed on the attached Exhibit A; and (ii) SLU’s rights, if any, to any patent (including, without limitation, any inventor’s certificate) that
has issued or issues in the future in any country including, without limitation, any reissue, reexamination, extension, confirmation, registration, revalidation, or patent of addition. 

  

	 	1.2	SLU will execute and deliver the instrument of assignment attached as Exhibit B. 

  

	 	2.	Payment. 

  

	 	2.1	In consideration for the assignment and transfer of SLU’s rights in the ‘710 Patent to ORCHID, as well as other good and valuable consideration: 

 

	 	2.1.1	ORCHID will pay SLU One Million Dollars ($1,000,000) according to the following schedule: Three Hundred Thousand Dollars ($300,000) upon full execution of this Agreement; Two
Hundred Fifty Thousand Dollars ($250,000) no later than the 15th day of January, 2003; Two Hundred Fifty Thousand
Dollars ($250,000) no later than the 15th day of July, 2003; and 

  

 1 

 Two Hundred Thousand Dollars ($200,000) no later than the 15th day of January 2004. 
  

	 	2.1.2	ORCHID shall also issue and deliver to SLU at Closing such number of unregistered shares (the “Shares”) of ORCHID common stock, par value $.001 per share (the “Common
Stock”) having a Fair Market Value (as defined below) equal to $500,000 pursuant to a Stock Purchase Agreement in the form attached as Exhibit C. As used herein, the term “Fair Market Value” shall mean either (1) the average
closing price per share of ORCHID Common Stock (rounded to the nearest cent) on The Nasdaq Stock Market (as reported in The Wall Street Journal, or, if not reported therein, any other authoritative source selected by ORCHID) for the twenty
(20) consecutive trading days ending on the second trading day immediately prior to full execution of the Settlement Agreement. or (2) the closing price per share of ORCHID Common Stock (rounded to the nearest cent) on The Nasdaq Stock Market (as
reported in The Wall Street Journal, or, if not reported therein, any other authoritative source selected by ORCHID) on the day prior to the full execution of the Agreement, whichever price is lower. 

  

	 	2.1.3	ORCHID shall register the Common Stock in accordance with the provisions of the Registration Rights Agreement attached as Exhibit E. 

  

	 	2.1.4	To the extent that SLU sells all of the Shares pursuant to the effective Resale Registration Statement and the aggregate gross proceeds received for such Shares is less than
$500,000, ORCHID hereby agrees to make a one-time payment to SLU equal to the difference between $500,000 and the amount of such aggregate gross proceeds (the “Make-up Payment”). The Make-up Payment may be paid to SLU by the issuance of
additional shares of Common Stock or by cash, at SLU’s sole discretion; provided, that, to the extent that ORCHID pays the Make-up Payment through the issuance of additional shares of Common Stock (a) the number of such shares so
issued shall be based on the Fair Market Value for either the twenty (20) consecutive trading days ending on the second trading day immediately prior to the latest date on which all or any portion of the Shares shall have been sold, or the date of
the latest sale of original share, whichever is lower; and (b) ORCHID shall have the obligation to register such additional shares in accordance with Section 2.1.3. SLU shall instruct the broker to sell the Shares within 60 days of when the
Registration becomes effective. 

  

	 	2.1.5	If, for whatever reason out of SLU’s reasonable control, Orchid is unable to register any amount of the Common Stock and/or SLU is unable to sell any of the ORCHID Shares by a
date one-hundred and eighty (180) days from the dated of the full execution of this Agreement, SLU may, at SLU’s sole discretion, (1) tender the remaining Shares back to ORCHID, in which case ORCHID will then immediately pay SLU in cash Five

  

 2 

 Hundred Thousand Dollars ($500,000.00) less the gross proceeds from the sale of any Shares originally
delivered to SLU pursuant to Section 2.1.2 and registered pursuant to Section 2.1.3; or (2) retain the Shares in full payment of the remaining unpaid $500,000 guaranteed sale price of such Shares. 
  
 2.2 To secure the above payments and delivery of Shares, Orchid will
contemporaneously execute and deliver the Security Agreement attached as Exhibit D and the Promissory Note attached as Exhibit F. 
  

	 	3.	Dismissal of Action. Upon execution of this Agreement, the parties shall dismiss the Action with prejudice with each party to bear its own costs and attorneys fees (except
that ORCHID will pay 100% of the fees incurred with the mediation held in connection with the Action on June 14, 2002). The parties agree that this Agreement is entered into for the purpose of avoiding the expense and inconvenience of litigation,
and that it is not to be construed as an admission of any sort by either party, except that ORCHID admits that U.S. Patent No. 5,846,710 is a valid patent. 

  

	 	4.	Representations and Warranties. 

  

	 	4.1	SLU represents and warrants that: 

  

	 	4.1.1	SLU is the legal and beneficial owner of all of its right, title and interest in and to the ‘710 Patent, recognizing that the United States Federal Government has a paid-up,
irrevocable license in the ‘710 patent and that there are two other non-exclusive licensees (Nanogen, Inc. and Illumina, Inc.) of the ‘710 Patent. 

  

	 	4.1.2	SLU has full power and authority and has taken all action necessary to enter into, execute and deliver this Agreement and effect the assignment and transfer contemplated hereby,
subject to Section 4.1.12 

  

	 	4.1.3	The execution and performance by SLU of this Agreement and all documents executed and delivered or required to be executed and delivered by it hereunder does not and will not
violate: (i) any law or regulation of the jurisdiction of its organization, (ii) any other law or regulation applicable to it including, without limitation, any applicable rule, law or regulation of any governmental authority with jurisdiction
subject to Section 4.l.6, (iii) any provision of its organizational documents, (iv) any order or judgment of any court or government authority applicable to it, or (v) any contractual restriction binding on it. 

  

	 	4.1.4	This Agreement has been duly executed and delivered by it and constitutes the legal, valid and binding obligation of SLU enforceable in accordance with its terms.

  

 3 

	 	4.1.5	SLU has not executed or entered into any agreement or assignment inconsistent with the assignment called for in Section 1 above. 

  

	 	4.1.6	All notices, consents or approvals of any nature whatsoever that may be required from any applicable governmental authority with jurisdiction including, without limitation, the NIH
(as defined below in Section 7.2) and the USPTO, or from a third party, in order for this Agreement and the assignment and sale contemplated hereby to be effective and valid will have been obtained, other than permission from the NIH to assign the
‘710 Patent to Orchid, and the consent of Illumina, both of which have been, or are in the process of being property requested by SLU in accordance with Section 5. 

  

	 	4.1.7	There are no liens, security interests, claims or encumbrances of any type with respect to the ‘710 Patent, other than the security interest granted to SLU by ORCHID pursuant
to this Agreement and the Security Agreement and other than the paid-up, irrevocable license granted to the Federal Government, and the non-exclusive licenses to Illumina and Nanogen, to the extent these licenses might be considered an encumbrance
on the ‘710 Patent 

  

	 	4.1.8	SLU is not aware of any challenges to the ‘710 Patent (whether with respect to scope, validity, inventorship or any other matter) made by any third party. Neither SLU, nor to
the knowledge of any executive officers of SLU, any third party, has made any such challenges, written or oral, or filed any application or document or otherwise taken any action that may affect the validity or scope of the ‘710 Patent.

  

	 	4.1.9	SLU has not received notice and is not aware of any infringement of the ‘710 Patent, other than the alleged infringement of Orchid and its customers or of any suit, action,
claim or proceeding involving the ‘710 Patent and no such suit, action, claim or proceeding (other than the Action) is currently pending with respect to the ‘710 Patent. 

  

	 	4.1.10	SLU has timely made all payments of fees or other costs heretofore due with respect to the ‘710 Patent (including the first maintenance fee) and no payments, fees or other
expenses will be outstanding as of the date this Agreement is fully executed. 

  

	 	4.1.11	To SLU’s knowledge, there are no continuation, divisional, continuation-in-part or foreign applications pending or patents that have issued on any continuation, divisional,
continuation-in-part or foreign applications that claim priority to an application to which the ‘710 Patent claims priority. 

  

	 	4.1.12	SLU will promptly provide to ORCHID any and all future correspondence to and from the NIH and the USPTO with respect to the ‘710 Patent and will take such other action or steps
as shall be necessary to appropriate to 

  

 4 

 assist Orchid in seeking and obtaining the permission of the NIH to the assignment of the ‘710
Patent to Orchid, as contemplated herein. 
  

	 	4.2	ORCHID represents and warrants: 

  

	 	4.2.1	ORCHID has full power and authority and has taken all action necessary to enter into, execute and deliver this Agreement and perform its obligations hereunder.

  

	 	4.2.2	The execution and performance by ORCHID of this Agreement and all documents executed and delivered or required to be executed and delivered by it hereunder does not and will not
violate any law or regulation of the jurisdiction of its organization or any other law or regulation applicable to it, any provision of its organizational documents, any order or judgment of any court or government authority applicable to it or any
contractual restriction binding on or affecting it or its assets. 

  

	 	4.2.3	This Agreement has been duly executed and delivered by it and constitutes the legal, valid and binding obligation of ORCHID enforceable in accordance with its terms.

  

	 	4.2.4	Upon SLU’s transfer of all of its right, title, and interest in the ‘710 Patent to ORCHID, ORCHID will (i) comply with and agrees to be subject to all laws, rules,
regulations and conditions applicable to the ‘710 Patent and including, without limitation, any applicable rule, law or regulation of any governmental authority with jurisdiction including, without limitation, the NIH and the USPTO, and more
specifically the terms and provision of 37 C.F.R. Section 401 et seq. and the Bayh-Dole Act, as amended, (ii). Shall further indemnify and hold harmless SLU from any obligations or claims hereafter arising under those licenses.

  

	5.	Satisfied Conditions. 

  

	 	5.1	The parties hereby stipulate that the following conditions have been met upon full execution of the Agreement: 

  

	 	5.1.1	SLU has delivered to ORCHID the original executed instrument of assignment in the form of attached Exhibit B. 

  

	 	5.1.2	At any time after the execution of this Agreement, upon Orchid’s reasonable request, SLU will deliver to ORCHID any and all non-privileged documents in SLU’s possession
with respect to the ‘710 Patent, to the extent not already produced by SLU during the Action. 

  

	 	5.1.3	SLU will have delivered to ORCHID all original written evidence of SLU’s title to, right, interest and obligations under the ‘710 Patent including, without limitation, any
requests for approval for the assignment and transfer of the ‘710 Patent from NIH. 

  

 5 

	 	5.1.4	SLU has delivered to ORCHID written approval of the assignment hereunder to ORCHID by Nanogen, Inc., a Delaware corporation. SLU has requested consent from Illumina, Inc., a
California Corporation for assignment of the Nonexclusive License Agreement dated January 20, 2000 between SLU and Illumina (“Illumina License Agreement”) to Orchid. SLU will use its reasonable best efforts to obtain such consent. In the
event Illumina withholds such consent, the parties agree that such withholding of consent is unreasonable and Orchid will indemnify and hold harmless SLU from any claims, actions or suits brought by Illumina against SLU as a result of the assignment
of the Illumina License Agreement to Orchid. 

  

	6.	Announcements. To the extent legal and practicable, ORCHID and SLU agree to issue a joint press release, the form of which will be positive and mutually agreed upon. The
parties further agree that the terms of this Agreement shall remain confidential and shall not be publicly disclosed, other than the assignment of the ‘710 Patent from SLU to ORCHID, and except as may be required (i) under the Registration
Statement to be filed pursuant to the Registration Rights Agreement or (ii) other applicable law or regulation. 

  

	7.	Remedies. 

  

	 	7.1	ORCHID agrees that if it breaches any of its material obligations under this Agreement and fails to cure such breach within sixty (60) days after SLU has notified ORCHID in writing
of such breach, it will pay SLU the future actual costs of collection, including attorneys’ fees, and will pay SLU Two Hundred Fifty Thousand Dollars ($250,000) for its past attorneys’ fees. 

  

	 	7.2	The parties agree that if the NIH fails to issue its approval to the assignment and transfer of the ‘710 Patent to Orchid, as requested, the ‘710 Patent assignment and
transfer set forth herein will be void and SLU will automatically and immediately, without further action or writing, grant to Orchid an exclusive (subject only to the non-exclusive right of the United States Federal Government (“NIH”),
Illumina and Nanogen) transferable, worldwide right and license, with the right to grant sublicenses, under the ‘710 Patent, to make, have made, use, sell, offer for sale, import, export and exploit in any manner any product or service or
otherwise practice and have practiced the method covered by the ‘710 Patent. The total consideration for such exclusive license will be equal to the payments and other consideration due under Section 2. The parties will enter into a separate
license agreement upon customary and reasonable terms and conditions as soon as practical after receipt of notice from the NIH of its determination to withhold consent to the assignment of the ‘710 Patent to Orchid and Orchid will reassign the
‘710 Patent to SLU upon execution of such license agreement. 

  

	8.	Release. ORCHID and SLU hereby release and forever discharge each other, their respective past and current officers, directors, employees, agents, attorneys, subsidiaries,
affiliates, successors and assigns, of all debts, damages, claims, actions and causes of action in law or in equity for or in account of any manner or thing that arose or could have arisen in connection with the Action; provided however that this
release does not 

  

 6 

 release or discharge either party from the obligations contained or described in this Agreement.

  

	9.	Privileged Documents. SLU has retained certain documents related to the ‘710 Patent and the Action that it has determined is covered by a privilege (the “Privileged
Documents”). SLU agrees that, to the best of its ability, it will maintain and enforce the Privileged Documents as privileged, consistently with respect to all third parties, in the same manner and to the same extent that SLU has heretofore
asserted a privilege at all times after execution of this Agreement. If any Privileged Document is challenged by any third party, SLU will give immediate notice of such challenge to Orchid. In the event SLU chooses to terminate or waive any
privilege related to any Privileged Document, or is compelled to do so by a court of law, SLU will immediately send to Orchid copies of the Privileged Document for which the privilege has been waived or terminated. 

  

	10.	Entire Agreement. This Agreement, together with all Exhibits and instruments attached hereto, constitutes the entire agreement among the parties pertaining to the subject
matter hereof and supersedes all prior agreements, letters of intent, understandings, negotiations and discussions of the parties, whether oral or written. 

  

	11.	Amendment. Any modification of this Agreement shall be in writing, signed by both parties. 

  

	12.	Disputes. Any dispute arising from or relating to this Agreement shall be governed by Missouri law and the parties agree that any action to enforce the terms of this
Agreement shall be brought in the United States District Court for the Eastern District of Missouri. 

  

	13.	Counterparts. The Agreement may be executed in one or more counterparts, and not necessarily on the same date, each of which shall be deemed an original and all of which
together shall constitute one and the same instrument. The parties agree to accept facsimile signatures. 

  

	14.	Binding Effect. This Agreement is binding upon and inures to the benefit of the heirs, successors and assigns of the parties hereto. 

  

	15.	Severability. If any provision of this Agreement is held to be invalid, illegal, unenforceable or void, it will be without effect on the validity, legality and enforceability
of the remaining provisions of this Agreement. Both parties will endeavor to replace the invalid, illegal, unenforceable or void provision with a valid and enforceable one that in its equitable effect is most consistent with the prior provision.

  

	16.	Notices. All notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the receiving party’s address set forth below or
to such other address as a party may designate by notice hereunder: 

  

	 	(a)	if to Orchid, to: 

  

	 	    	Orchid BioSciences, Inc. 

	 	    	4390 US Route One 

	 	    	Princeton, NJ 

	 	    	Attention: Kevin Nash, Esq. 

	 	    	Fax: 609-750-2250 

  

	 	    	with a copy to: 

  

	 	    	Kalow & Springut, LLP 

	 	    	488 Madison Avenue 

	 	    	New York, NY 10022 

	 	    	Attn: David A. Kalow, Esq. 

	 	    	Fax: 212-813-9600 

  

	 	(b)	if to SLU, to: 

  

	 	    	Saint Louis University 

	 	    	221 North Grand Boulevard 

	 	    	St. Louis, Missouri 63103 

	 	    	Attn: Robert O. Webster, Ph.D. 

	 	    	Fax: 314-268-5551 

  

	 	    	with a copy to: 

  

	 	    	Saint Louis University 

	 	    	221 North Grand Boulevard 

	 	    	St. Louis, Missouri 63103 

	 	    	Attn: Kenneth E. Fleischmann, Esq. 

	 	    	Fax: 314-977-7186 

  

 7 

	 	    	and 

  

	 	    	Lewis, Rice & Fingersh 

	 	    	500 North Broadway, Suite 2000 

	 	    	St. Louis, Missouri 63102 

	 	    	Attn: Frank B. Janoski, Esq. 

	 	    	Fax: 314-241-6056 

  
 All notices, requests, consents and other communications hereunder shall be deemed to have been given either (i) if by hand, at the time of the delivery
thereof to the receiving party at the address of such part set forth above, (ii) if made by telex, telecopy or facsimile transmission, at the time that receipt thereof has been acknowledged by electronic confirmation or otherwise, (iii) if sent by
overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iv) if sent by registered or certified mail, on the 5th business day following the day such mailing is made. 
  

	17.	Construction. Each Party acknowledges and agrees that: (i) its counsel reviewed and negotiated the terms and conditions of this Agreement and have contributed to its
revision; (ii) it understands and agrees to be bound by the terms and conditions of this Agreement; (iii) the rule of construction to the effect that any ambiguities are resolved against the drafting party will not be employed in the interpretation
of this Agreement; and (iv) the terms and provisions of this Agreement will be construed fairly as to all parties hereto and not in a favor of or against any party, regardless of which party was generally responsible for the preparation of this
Agreement. 

  

 8 

 IN WITNESS WHEREOF, the parties caused this Agreement to be properly executed as of the date first
above written. 
  

			
	ORCHID BIOSCIENCES, INC.
		
	By:	 	 
	 	 	

	 Name:
	 	 Donald Marvin

	 Title:
	 	 Chief Operating Officer

  

			
	SAINT LOUIS UNIVERSITY
		
	 By:
	 	 
	 	 	

	 Name:
	 	 Robert O. Webster, PhD

	 Title:
	 	 Associate Provost for Research Administration

  

 9 

 Exhibit A 
  

List of Agreements and Licenses 
  
  
 [*] 
  

 10 

 Exhibit B 
  

Assignment 
  
 In consideration of One Dollar (US $1.00) and the payments made to Assignor pursuant to the Settlement Agreement dated June 14, 2002 between the parties,
together with other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned, 
  
 SAINT LOUIS UNIVERSITY, a non-profit organization organized and existing under the laws of the State of Missouri with a principal location in St. Louis
Missouri (“Assignor”) 
  
 Hereby sells, assigns
and transfers to 
  
 ORCHID BIOSCIENCES, INC., a Delaware
Corporation with a principal location in Princeton, New Jersey (“Assignee”) all of its right, title or interest, including all rights for all countries, in and to any and all inventions that are disclosed and claimed, and any and
all inventions that are disclosed but not claimed, in the applications and patents listed in Schedule A, and in and to said patents or applications and all divisional, continuation, continuing, substitute, renewal, reissue and all other
applications for patents or other related property rights in any and all countries that have been or shall be filed on any of said inventions disclosed in said patents or applications; and in and to all original and reissued patents or related
foreign documents that have been or shall be issued on said inventions; 
  
 Authorizes and requests the Director of Patents of the United States to issue to Assignee, its successors, assigns and legal representatives, in accordance with this assignment, any and all United States Letters Patent on said
inventions or any of them disclosed in said applications; 
  
 Agrees that Assignee may apply for and receive foreign Letters Patent or rights of any other kind for said inventions, or any of them; and may claim, in applications for said foreign Letters Patent or other rights, the priority of
the United States patents and applications in Schedule A under the provisions of the International Convention of 1883 and later modifications thereof, under the Patent Cooperation Treaty, under the European Patent Convention or under any
other available international agreement; and that, when requested, without charge to, but at the expense of, Assignee, its successors, assigns and legal representatives, to carry out in good faith the intent and purpose of this assignment, the
Assignor or the executors or administrators of the Assignor will, for the United States and all foreign countries, execute all original, divisional, continuation, continuing, substitute, renewal, reissue, and all other patent applications or other
documents on any and all said inventions; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to Assignee, its successors, assigns and representatives, all facts known and documents available to the Assignor
relating to said inventions and the history thereof; and testify in all legal proceedings regarding said patent; and 
  
 Covenants with said Assignee, its successors, assigns and legal representatives that no assignment, grant, mortgage, license or other agreement
affecting the rights and property herein 
  

 11 

 conveyed has been made to others by Assignor, and that full right to convey the same as herein expressed is possessed by
Assignor, and: 
  
 FURTHER, THAT: 
  
 Assignee agrees that it, its successors, assigns and legal
representatives will be subject to and will comply with the terms and provisions of all federal law, rules and regulations applicable to said patent, including but not limited to the terms and provisions of 37 C.F.R.§ 401 et seq. and the
Bayh-Dole Act, as amended, in commercializing the technology covered by said patent. 
  
 Assignee does: 
 Agree to and accept the assignment hereunder. 
  
 Date: August 6, 2002 
  

			
	 ASSIGNOR:
  
 SAINT LOUIS UNIVERSITY

		
	By:	 	 
	 	 	

	 	 	Signature
	Name:	 	Robert O. Webster, Ph.D.
	Title:	 	 Associate Provost for Research
 Administration

Duly authorized to sign on behalf of
 Assignor

  
 STATE OF                    ) 
 COUNTY OF                ) 
  
 On this 6th day of August 2002, personally appeared before me, Robert O. Webster, known or identified to me as the Associate Provost for Research Administration of St.
Louis University, who executed the foregoing and acknowledged the same as a free act and deed for uses and purposes therein expressed. 
  

	
	
	 
	

	Notary Public

  

 12 

 ASSIGNEE: 
  

									
	 	 	 	 	 ORCHID BIOSCIENCES, INC.

					
	Date:	 	August 6, 2002 By: 	 	 	 	By:	 	 
	 	 	 	 	 	 	 	 	

	 	 	 	 	 	 	 	 	Signature
	 	 	 	 	 	 	 Name:
	 	Kevin B. Nash
	 	 	 	 	 	 	 Title:
	 	 Executive Director of Legal Affairs
 Duly authorized
to sign on behalf of
 Assignee

  
 STATE
OF                    ) 
 COUNTY OF                ) 
  
 On this 6th day of August 2002, personally appeared before me, Kevin B. Nash known or identified to me to be the Executive Director of Legal Affairs of Orchid
BioSciences, Inc. and the individual who executed the foregoing and acknowledged the same as a free act and deed for uses and purposes therein expressed. 
  

	
	
	 
	

	Notary Public

  

 13 

 Schedule A 
  
 ASSIGNED PATENT APPLICATIONS AND PATENTS 
  
 United States 
  
 U.S. Patent No. 5,846,710 entitled Method for the Detection of Genetic Diseases and Gene Sequence Variations by Single Nucleotide Primer Extension, issue date December 8, 1998. 
  

 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]